Researchers have demonstrated that cerebral organoids grown at the air–liquid interface are able to generate nerve tracts and stimulate muscle output; these could be used to improve understanding of neurological diseases such as dementia.
A team of neuroscientists has identified a group of cells in the hippocampus that can control fear memories. Understanding the mechanisms by which these cells activate and suppress memories could improve therapies for fear-based disorders.
A recent transnational study has determined that daily use of high potency cannabis can increase the risk of developing psychotic disorder.
For the first time in over 30 years, the US FDA has approved a new antidepressant called Spravato™ (esketamine) for treatment-resistant depression in adults.
Cannabis use amongst adolescents has been associated with increased risk of depression and anxiety in adulthood, according to a new study.
In the largest study of its kind, researchers have identified hundreds of genes newly linked to depression, shedding light on the origins of the condition.
Common somatic medications used to combat physical health diseases could bring significant benefits to people with mental illnesses.
This week we look at NurOwn® for multiple sclerosis, a combination therapy failing to meet primary endpoint for glioblastoma and warnings from the US FDA.
New studies in which animal models have been utilized to study opioid addiction, withdrawal and relapse may offer insights into managing the opioid epidemic in humans.
Three studies have been highlighted at SfN Neuroscience on the links between adolescent brain development, mental health and substance abuse.